Preparation methods of nitrogen-containing heterocyclic compounds
Patent Information
- Application Number
- TW112106447
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-22
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-02-21
AI Technical Summary
The existing preparation method for nitrogen-containing heterocyclic compounds, specifically targeting DPP1 inhibitors, faces challenges such as difficulty in purifying intermediates, multi-step column purification, low yield, and high cost, making it unsuitable for large-scale industrial production.
A four-step method involving coupling, deprotection, amidation, and deprotection reactions is employed, using specific catalysts and solvents under controlled conditions to enhance reaction efficiency and simplify purification processes, allowing for high yield and suitability for industrial scale-up.
The method achieves high purity and yield of the target compound, suitable for industrial production, with good activity, bioavailability, and low toxicity, demonstrating potential as a therapeutic agent for lung diseases.
Abstract
Description
Technical Field
[0001] This invention relates to a method for preparing nitrogen-containing heterocyclic compounds. Prior Technology
[0002] Dipeptidyl peptidase 1 (DPP1), also known as cathepsin C, is a cysteine protease belonging to the lysosomal papain family, involved in intracellular protein degradation. During neutrophil maturation, DPP1 initiates neutrophil serine proteases (NSPs) by cleaving the N-terminal dipeptide of target proteins, including neutrophil elastase (NE), proteinase 3 (Pr3), and cathepsin G (CatG). DPP1 is associated with various inflammatory diseases, including Wegener's granulomatosis, rheumatoid arthritis, lung inflammation, and viral infections. Studies have shown that inhibiting DPP1 can have a good therapeutic effect on highly inflammatory lung diseases caused by neutrophils, such as bronchiectasis, chronic obstructive pulmonary disease (COPD), and acute lung injury. Therefore, targeting DPP1 and inhibiting the overactivation of NSPs may have a potential therapeutic effect on bronchiectasis.
[0003] Patent application PCT / CN2020 / 114500 describes the preparation of a small molecule DPP1 inhibitor of formula (I). This compound exhibits high DPP1 inhibitory activity, excellent bioavailability and pharmacokinetic characteristics, and low toxicity and high safety profile, and is intended for the treatment of lung diseases such as noncystic fibrotic bronchiectasis, chronic obstructive pulmonary disease (COPD), acute lung injury, and cystic fibrotic bronchiectasis. However, the preparation method described in this patent has drawbacks, including difficult intermediate purification requiring multiple column purification steps, unfavorable reaction conditions for scale-up production, low yield, and high cost. Therefore, it is necessary to improve the preparation technology to adapt it for large-scale industrial production. Summary of the Invention
[0004] This invention provides a method for preparing a compound of formula (I).
[0005] It includes the first step: coupling compound 2a and compound 1A to obtain intermediate 1B;
[0006] And the second step: deprotecting intermediate 1B to obtain intermediate 1C or its salt; .
[0007] The starting compounds 2a and 1A can be synthesized by referring to the methods described in existing chemical reference books, literature, patents, etc., or purchased commercially. For example, the preparation method of compound 1A is described in patent WO2015110826A1 (50 pages), and the preparation method of compound 2a is described in WO2016139355A1 (52 pages).
[0008] The coupling reaction in the first step can usually be carried out under alkaline conditions using a catalyst such as palladium or nickel. The palladium or nickel reagent includes, but is not limited to, one or more of the following: NiCl₂, NiCl₂·diglyme (diethylene glycol dimethyl ether nickel dichloride), Ni(COD)₂, Pd(OAc)₂, PdCl₂, Pd(PPh₃)₂Cl₂, Pd(dppf)Cl₂, Pd(PPh₃)₄, Pd₂(dba)₃, Pd(PhCN)₂Cl₂, PEPPSI-iPr, PdCl₂[P(Cy)₃]₂, or [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (Pd(dppf)Cl₂·CH₂Cl₂). The alkaline reagent used to prepare the alkaline conditions includes, but is not limited to, K₃PO₄, K₂HPO₄, K₂CO₃, and KHCO₃. 3. Cs₂CO₃, Na₂CO₃, NaHCO₃, KF, sodium acetate, potassium acetate, pyridine, triethylamine or N,N-diisopropylethylamine, or one or more of their aqueous solutions;
[0009] In some specific embodiments, the first step includes dissolving compound 2a and compound 1A in an organic solvent capable of dissolving the reactants, including but not limited to acetonitrile, toluene, dichloromethane, ethyl acetate, acetone, methanol, ethanol, isopropanol, 2-methyltetrahydrofuran, tetrahydrofuran, and 1,4-dioxane. Then, one or more of the following are added: K₃PO₄, K₂HPO₄, K₂CO₃, KHCO₃, Cs₂CO₃, Na₂CO₃, NaHCO₃, KF, sodium acetate, potassium acetate, pyridine, triethylamine, or N,N-diisopropylethylamine, or aqueous solutions thereof. After the addition is complete, one or more of the following are added: NiCl₂, NiCl₂·diglyme, Ni(COD)₂, Pd(OAc)₂, PdCl₂, Pd(PPh₃)₂Cl₂, Pd(dppf)Cl₂, and Pd(PPh₃). 4. One or more catalysts selected from Pd₂(dba)₃, Pd(PhCN)₂Cl₂, PEPPSI-iPr, PdCl₂[P(Cy)₃]₂, and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (Pd(dppf)Cl₂·CH₂Cl₂) are used. Under nitrogen protection, the mixture is heated to 80±5℃ for complete reaction. Then, purified water or ethanol is added to the reaction solution, or the temperature is directly lowered to 5-55℃, filtered, and dried to obtain intermediate 1B. Optionally, after filtration, the filter cake is added to an alcohol solvent, stirred for 10 min to 2 h, then filtered and dried to obtain intermediate 1B. Unless otherwise specified, the alcohol solvent includes, but is not limited to, methanol, ethanol, propanol, isopropanol, n-butanol, etc. Under these reaction conditions, this step has a fast reaction rate, high conversion rate, simple post-processing, and high purity.
[0010] In some specific implementations, the first step is to purge with nitrogen before adding the catalyst, and then purge with nitrogen again after adding the catalyst. The purpose of this is to fully remove oxygen from the reaction system and avoid catalyst deactivation.
[0011] In some specific embodiments, the feed ratio of the first step reaction ranges from 2a:1A:palladium agent = 1:1.0~3.0:0.001~0.2, preferably 2a:1A:palladium agent = 1:0.95~1.20:0.001~0.03, and the amount of potassium carbonate added ranges from 2a:K2CO3 = 1.0:1.5~8.0, preferably 2a:K2CO3 = 1.0:2.0~3.0.
[0012] In some specific embodiments, the second step involves adding intermediate 1B and an acid to an organic solvent and reacting them at a controlled temperature of 20-55°C until fully soluble. The mixture is then filtered to obtain intermediate 1C or its salt. Optionally, the filter cake is added to the organic solvent, heated to 80±5°C, stirred for 1-5 hours, cooled to 20±5°C, stirred, filtered, and dried to obtain intermediate 1C or its salt. The acid is selected from one or more of sulfuric acid, phosphoric acid, formic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid, and p-toluenesulfonic acid monohydrate. The organic solvent is selected from one or more of methanol, ethanol, isopropanol, acetonitrile, isopropyl acetate, ethyl acetate, toluene, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran, methyl tributyl ether, and acetonitrile.
[0013] The deBoc protection reaction typically involves dissolving the intermediate and acid in an organic solvent and controlling the reaction at a specific temperature. The acid includes, but is not limited to, sulfuric acid, phosphoric acid, formic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid, and p-toluenesulfonic acid monohydrate. The organic solvent includes, but is not limited to, methanol, ethanol, isopropanol, acetonitrile, isopropyl acetate, ethyl acetate, toluene, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran, methyl tributyl ether, and acetonitrile. The temperature is approximately 0°C to 80°C.
[0014] In some specific embodiments of the present invention, in the second step, intermediate 1B and p-toluenesulfonic acid monohydrate are added to acetonitrile and reacted fully at a controlled temperature of 25±5℃; then filtered, and the filter cake is added to acetonitrile, heated to 80±5℃, stirred for 1 to 5 hours, cooled to 20±5℃, stirred, filtered, and dried to obtain intermediate 1C or its salt.
[0015] The second step of the present invention preferably uses p-toluenesulfonic acid monohydrate as an acid and reacts in acetonitrile. Its advantages are that the reaction is fast, the product precipitates directly after the reaction is completed, and the product can be obtained by filtration. The operation is simple. The advantage of the subsequent high-temperature stirring in acetonitrile is that the hot pulping has a good effect on removing impurities and the product is not easy to absorb moisture.
[0016] In some specific embodiments, the molar ratio of the feed for the second step reaction is 1B:acid = 1:1.0~5.0; in some embodiments, it is preferred to be 1B:acid = 1:1.5~3.0.
[0017] In some specific embodiments, the preparation method of formula (I) of the present invention further includes
[0018] Step 3: Intermediate 1C or its salt is subjected to an amination reaction with compound INT-3 or its salt to obtain intermediate 1D; ; or / and
[0019] Step 4: Intermediate 1D is deprotected under acidic conditions to yield compound (I) or its salt; .
[0020] The third step, amide reaction, can usually be carried out by dehydration under condensing agent and alkaline conditions.
[0021] In some specific embodiments, the third step involves adding intermediate 1C or its salt, and compound INT-3 or its salt, to an organic solvent, followed by the addition of an organic amine. After the addition is complete, an acid-amine condensing agent is added under nitrogen protection at a controlled temperature of 5-20°C. After the addition is complete, the mixture is kept at 25±5°C for complete reaction. Then, the reaction solution is washed with sodium chloride solution, separated, and pharmaceutical charcoal or activated carbon is added to the organic phase. The mixture is stirred, filtered, and dried with anhydrous sodium sulfate. After filtration and concentration, intermediate 1D is obtained.
[0022] The organic solvent is selected from one or more of tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, acetone, methyl isobutyl ketone, isopropyl acetate, and ethyl acetate.
[0023] The organic amine is selected from one or more of triethylamine, 2,6-dimethylpyridine, pyridine, DBU, and N,N-diisopropylethylamine;
[0024] The acid-amine condensing agent is selected from one or more of HATU, COMU, EDCI, BOP, and propylphosphine.
[0025] In some specific embodiments, the material ratio range of the third step is 1C:INT-3=1:0.9~3.0, preferably 1C:INT-3=1:1.0~1.5, and the amount of condensing agent is usually 1C:condensing agent=1:1.0~5.0, preferably 1C:condensing agent=1:1.2~2.0.
[0026] In some specific embodiments, the third step involves washing the reaction solution sequentially with an alkaline aqueous solution and an acidic aqueous solution before washing it with sodium chloride solution; the alkaline aqueous solution is selected from one or more of potassium phosphate solution, potassium carbonate solution, potassium bicarbonate solution, sodium carbonate solution, and sodium bicarbonate solution. The purpose of this washing step is to remove unreacted 1C or INT-3 through acid washing and alkaline washing.
[0027] The fourth step, the deprotection reaction, is usually carried out under acidic conditions in an organic solvent.
[0028] In some specific embodiments, in the fourth step, intermediate 1D and an acidic reagent are added to an organic solvent. After the addition is complete, the mixture is kept at 25±5℃ to react fully. Then, alkali is added dropwise to the reaction solution while the temperature is controlled below 25℃. After the addition is complete, the temperature is lowered to 10±5℃ to crystallize. The mixture is then filtered and dried to obtain compound (I). Optionally, after filtration, the filter cake is washed with purified water, and then the filter cake is added to ethanol, stirred at 20±5℃, filtered, and dried to obtain compound (I) or its salt.
[0029] The advantage of using the above conditions in the fourth step of the reaction is that after deprotection, the alkali is adjusted, the product precipitates directly, and it can be obtained by filtration, making the post-processing simple.
[0030] In some specific embodiments, the acidic reagent in step four is selected from one or more of hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid, and p-toluenesulfonic acid monohydrate; the organic solvent is selected from one or more of acetonitrile, acetonitrile, methanol, ethanol, isopropanol, isopropyl acetate, ethyl acetate, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran, and methyl tributyl ether; and the base is selected from one or more of dilute ammonia, LiOH, NaOH, KOH, K₃PO₄, K₂CO₃, KHCO₃, Cs₂CO₃, Na₂CO₃, and NaHCO₃.
[0031] In some specific embodiments, the material ratio in the fourth step is in the range of 1D:acid = 1.0:1.0~6.0, preferably 1D:acid = 1.0:2.0~4.0, and the amount of alkali added is in the range of 1D:alkali = 1.0:2.0~10.0, preferably 1D:alkali = 1.0:3.0~6.0.
[0032] In some specific embodiments, the fourth step also includes a purification step: recrystallizing the obtained compound (I) using recrystallization reagents including, but not limited to, acetonitrile, methanol, ethanol, isopropanol, isopropyl acetate, ethyl acetate, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran, n-heptane, methyl tributyl ether, dimethyl sulfoxide, N-methylpyrrolidone and their mixed solvents.
[0033] In some specific embodiments, the fourth purification step is as follows: the obtained compound (I) is added to a mixed solution of anhydrous ethanol-water, acetonitrile-water, acetonitrile-methanol, acetonitrile-isopropanol, acetonitrile-tert-butanol, acetonitrile-n-butanol, or acetonitrile-anhydrous ethanol, heated to 75±5℃, stirred until dissolved, optionally hot filtered, the filtrate is cooled and crystallized while stirring, filtered, dried, and the purified compound (I) is obtained.
[0034] In some specific embodiments, the volume ratio of crude product to solvent in the refining step ranges from 1.0:10.0 to 40.0, and is preferably 1.0:12.0 to 20.0.
[0035] In some specific embodiments, the fourth step of crystallization by stirring and cooling is carried out in two steps: first, the temperature is lowered to 35±5℃ and held at that temperature for 20 min to 1.5 hours for crystallization, and then the temperature is lowered to 5±5℃ and held at that temperature for 1 to 3 hours for crystallization. The advantage of stepwise crystallization is that it has a good impurity removal effect and a high yield.
[0036] The complete reaction described in this invention refers to a reaction state in which the content of the main raw materials is ≤1.0% when samples are taken and monitored by HPLC.
[0037] The salts of this invention refer to salts formed by acidic compounds and organic or inorganic bases, or by basic compounds and organic or inorganic acids, such as triethanolamine salts, diethanolamine salts, monoethanolamine salts, carbonates, bicarbonates, hydrobromide salts, hydrochloride salts, sulfates, malate salts, fumarate salts, tartrate salts, oxalate salts, citrate salts, benzenesulfonate salts, p-toluenesulfonate salts, etc.
[0038] Salt preparation is well known in the art; for example, a compound is reacted with an acid or base in a solvent, and the corresponding salt is separated by precipitation, filtration, or other methods. Similarly, using salts to replace free acids or bases in chemical reactions is also well known in the art. When describing a reaction in which a compound prepares another substance, this invention includes the use of its salt form in the reaction, and the product may also be obtained in salt form. If the product is a salt, it is dissolved in a solvent, neutralized with the corresponding acid or base, and after the compound is released, conventional post-treatment methods can be used to obtain the free compound.
[0039] The preparation method of this invention is very simple to operate, with high yields of intermediates synthesized in each step, greatly improving the overall yield and thus reducing production costs. All intermediate products in the synthesis process can be crystallized and purified, achieving high purity and high yield, making it suitable for large-scale industrial production.
[0040] Unless otherwise specified, the operations of this invention are performed in accordance with conventional procedures in the art. References and monographs in the art provide detailed descriptions of the synthesis of reactants that can be used to prepare the compounds described herein, or provide articles describing the preparation methods for reference. These references and monographs include: “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; SR Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; HO House, “Modern Synthetic Reactions”, 2nd Ed., WA Benjamin, Inc. Menlo Park, Calif. 1972; TL Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure”, 4th Ed., Wiley-Interscience, New York, 1992. [;]Fuhrhop, J. and Penzlin G. “Organic Synthesis: Concepts, Methods, Starting Materials”, Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3‑527-29074-5; Hoffman, R.V. “Organic Chemistry, An Intermediate Text” (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. “Comprehensive Organic Transformations: A Guide to Functional Group Preparations” 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure” 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) “Modern Carbonyl Chemistry” (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. “Patai’s 1992 Guide to the Chemistry of Functional Groups” (1992) Interscience ISBN: 0-471-93022-9; Solomons, T. W. G. “Organic Chemistry” 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., "Intermediate Organic Chemistry" 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, in over 55 volumes; and “Chemistry of Functional Groups” John Wiley & Sons, in 73 volumes. . Simple Diagram Explanation
[0041] without Implementation method
[0042] The following embodiments will provide a detailed description of the invention. Where specific conditions are not specified in the embodiments, experimental methods under conventional conditions shall apply. The embodiments provided are for the purpose of better illustrating the invention, but should not be construed as limiting the invention to the examples given. Any non-essential improvements and adjustments made to the embodiments by those skilled in the art based on the above-described invention are still within the scope of protection of this invention.
[0043] [Detection Method] []
[0044] The structure of the compounds was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) are given in units of 10⁻⁶ (ppm). NMR determinations were performed using Bruker Avance III 400 and Bruker Avance 300 NMR spectrometers, with deuterated dimethyl monoxide (DMSO-d₆), deuterated chloroform (CDCl₃), and deuterated methanol (CD₃OD) as solvents, and tetramethylsilane (TMS) as the internal standard.
[0045] MS determination was performed using (Agilent 6120B (ESI) and Agilent 6120B (APCI));
[0046] HPLC determinations were performed using an Agilent 1260DAD high-performance liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM).
[0047] [Preparation of Compounds] []
[0048] This invention prepares the target compound in four steps: a coupling reaction between compound 1A and compound 2a, followed by sequential deprotection, amide formation, and deprotection. The route is short, the conditions are mild, the operation is simple, post-processing is convenient, and the yield and purity are high, making it suitable for industrial-scale production. Target compound I exhibits good activity, high bioavailability, and low toxicity, demonstrating potential for drug development.
[0049] [Example] [1] []
[0050] Tertiary butyl(S)-(1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)carbamate (1B)
[0051] tert-butyl(S)-(1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)carbamate (1B)
[0052] Method 1:
[0053] Add 10.005 kg of 1,4-dioxane, 1.600 kg of compound 1A (using the method described in patent WO2015110826A1), and 2.000 kg of compound 2a (using the method described in patent WO2016139355A1) to a 50L reactor with stirring. Then add 6.605 kg of potassium carbonate aqueous solution (1.600 kg of potassium carbonate dissolved in 5.005 kg of purified water). After the addition is complete, purge the mixture with nitrogen three times. Add 100.0 g of [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex, and purge with nitrogen once. Under nitrogen protection, heat the reaction solution to 80±5℃ and react for about 2 hours. Take a sample for HPLC monitoring. If the content of compound 2a is ≤1.0%, stop the reaction.
[0054] Add 5.000 kg of purified water to the reaction solution, cool to 10±5℃, add 10.005 kg of purified water, stir at 10±5℃ for about 1 hour to induce crystallization, filter, wash the filter cake twice with 2.500 kg of purified water each time, and collect the filter cake. Add 12.605 kg of anhydrous ethanol and the filter cake to a 50 L reactor, stir at 20±5℃ for about 0.5 hours, filter, wash the filter cake twice with 1.000 kg of anhydrous ethanol each time, and collect the filter cake.
[0055] Drying: The filter cake was dried at 55±5℃ and vacuum ≤-0.07MPa for about 16 hours, yielding 2.143 kg of intermediate 1B, with a yield of 89.4% (HPLC: 95.91%).
[0056] 1H NMR (400 MHz, DMSO) δ 7.90 (s, 1H), 7.72 – 7.30 (m, 6H), 4.72 (s, 1H), 3.41 (d, 3H), 3.09-3.21(m, 2H), 1.37 (s, 9H).
[0057] LCMS m / z =356.1[M-56+H] +.
[0058] Method 2:
[0059] To a 1L reaction flask, add 100g acetonitrile, 20.15g compound 1A, and 16.02g compound 2a with stirring, followed by 16.57g of potassium carbonate aqueous solution (16.53g potassium carbonate dissolved in 40g purified water). After the addition is complete, purge the solution three times with nitrogen. Add 0.83g of the [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex. Under nitrogen protection, heat the reaction solution to 80±5℃ and react for approximately 2 hours, then stop the reaction.
[0060] Cool the reaction solution to 50±5℃, add 80g of anhydrous ethanol, allow crystals to precipitate for about 1 hour, filter, wash the filter cake with 20g of anhydrous ethanol, and collect the filter cake.
[0061] Drying: The filter cake was dried at 55±5℃ and vacuum ≤-0.07MPa for about 16 hours, yielding 24.41g of intermediate 1B, with a yield of 83.0%.
[0062] Method 3:
[0063] Add 5.5 kg of 1,4-dioxane, 0.551 kg of compound 1A, and 0.434 kg of compound 2a to a 20 L reactor with stirring, followed by 1.744 kg of potassium carbonate aqueous solution (0.444 kg of potassium carbonate dissolved in 1.30 kg of purified water). After the addition is complete, purge with nitrogen three times. Add 208 g of the [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex. Under nitrogen protection, heat the reaction solution to 80 ± 5 °C and react for approximately 3 hours, then stop the reaction.
[0064] Cool the reaction solution to 20±5℃, stir to induce crystallization for about 1 hour, filter, wash the filter cake twice with 1.0 kg purified water each time, and collect the filter cake. Add 3.2 kg anhydrous ethanol and the filter cake to a 20 L reactor, heat to 70±5℃ and stir for about 1.5 hours, cool to room temperature, filter, wash the filter cake with 1.20 kg anhydrous ethanol, and collect the filter cake.
[0065] Drying: The filter cake was dried at 55±5℃ and vacuum ≤-0.07MPa for about 18 hours, yielding 0.435 kg of intermediate 1B, with a yield of 74.0%.
[0066] [Example] [2] []
[0067] (S)-2-amino-3-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)propionitrile 4-methylbenzenesulfonate (1C methanesulfonate)
[0068] (S)-2-amino-3-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)propanenitrile 4-methylbenzenesulfonic acid (1C 4-methylbenzenesulfonic acid)
[0069] Method 1:
[0070] Add 16.785 kg of acetonitrile, 2.1381 kg of intermediate 1B, and 2.950 kg of p-toluenesulfonic acid monohydrate to a 50L glass reactor with stirring. After the addition is complete, react at 25±5℃ for about 2 hours, and then take a sample for HPLC monitoring. If the intermediate 1B content is ≤1.0%, stop the reaction.
[0071] Filter the mixture, wash the filter cake with 1.670 kg of acetonitrile, and collect the filter cake. Add 2.1381 kg of acetonitrile and the filter cake to the reactor, heat to 80±5℃, and stir for 3 hours. Then cool to 20±5℃ and stir for 1 hour. Filter the mixture, wash the filter cake with 1.670 kg of acetonitrile, and collect the filter cake.
[0072] Drying: The filter cake was dried at 55±5℃ and vacuum ≤-0.07MPa for about 16 hours. 2.141 kg of intermediate 1C methanesulfonate was obtained, with a yield of 85.5% (HPLC: 99.43%).
[0073] 1H NMR (400 MHz, DMSO) δ 9.04 (s, 3H), 7.70 – 7.37 (m, 8H), 7.13 (d, 2H), 4.90 (dd, 1H), 3.41 (s, 3H), 3.29 (t, 2H), 2.29 (s, 3H).
[0074] LCMS m / z =312.2 [M-172+H] +.
[0075] Method 2:
[0076] Add 400 g acetonitrile, 50.30 g intermediate 1B, and 69.30 g p-toluenesulfonic acid monohydrate to a 1 L reaction flask with stirring. After the addition is complete, react at 50±5℃ for about 1 hour, then monitor the reaction by HPLC. If the content of intermediate 1B is ≤1.0%, stop the reaction. Filter, wash the filter cake with 10 g acetonitrile, and collect the filter cake.
[0077] Drying: The filter cake was dried at 55±5℃ and under vacuum ≤-0.07MPa for approximately 24 hours. 55.70 g of intermediate 1C methanesulfonate was obtained, with a yield of 95.0%.
[0078] Method 3:
[0079] Add 160 g acetonitrile, 20.3 g intermediate 1B, and 17.8 g concentrated hydrochloric acid to a 0.5 L reaction flask with stirring. After the addition is complete, react at 25 ± 5 °C for approximately 2 hours, then monitor the reaction with HPLC. If the content of intermediate 1B is ≤ 1.0%, stop the reaction. Filter the mixture, wash the filter cake with 10 g acetonitrile, and collect the filter cake.
[0080] Drying: The filter cake was dried at 55±5℃ and vacuum ≤-0.07MPa for about 18 hours. 14.4g of intermediate 1C hydrochloride was obtained, with a yield of 85.0%, and it is hygroscopic.
[0081] [Example] [3] []
[0082] Tertiary butyl(S)-2-(((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)aminomethoxy)-1,4-oxazacycloheptane-4-carboxylic acid ester (1D)
[0083] tert-butyl(S)-2-(((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)carbamoyl)-1,4-oxazepane-4-carboxylate (1D)
[0084] Method 1:
[0085] To a 50L reactor, 19.060 kg of ethyl acetate, 2.1413 kg of intermediate 1C, and 1.1300 kg of INT-3 (purchased from Nanjing Yaoshi Technology Co., Ltd.) were added with stirring, followed by 1.725 kg of N,N-diisopropylethylamine. After the addition was complete, under nitrogen protection, the reaction solution was cooled to 5±5℃, and 4.240 kg of propylphosphonic anhydride was added dropwise while maintaining the temperature at 10±5℃. After the addition was complete, the reaction was maintained at 25±5℃ for approximately 2 hours. HPLC monitoring was then performed, and the reaction was stopped when the intermediate 1C content was ≤1.0% according to the target value.
[0086] The reaction mixture was washed sequentially with sodium bicarbonate solution (1.070 kg sodium bicarbonate dissolved in 20.350 kg water), citric acid solution (2.150 kg citric acid monohydrate dissolved in 19.275 kg water), and sodium chloride solution (4.300 kg sodium chloride dissolved in 17.135 kg water). 0.210 kg of pharmaceutical-grade charcoal was added to the organic phase, and the mixture was stirred for approximately 0.5 hours. The mixture was filtered through a 0.540 kg diatomaceous earth filter, and the filter cake was washed with 1.905 kg of ethyl acetate. 1.070 kg of anhydrous sodium sulfate was added to the organic phase, and the mixture was dried for approximately 0.5 hours. The mixture was then filtered, and the filter cake was washed with 1.905 kg of ethyl acetate. The filtrates were combined.
[0087] The filtrate was concentrated under reduced pressure at 50±5℃ until no significant fraction was eluted, yielding 2.385 kg of intermediate 1D (overweight, calculated based on a 100% yield). It was used directly in the next reaction; HPLC: 99.09%.
[0088] 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.01 (m, 7H), 5.18 (s, 1H), 4.25 – 3.94 (m, 3H), 3.54 (dd, 2H), 3.46 (s, 3H), 3.39 – 3.04 (m, 4H), 1.99 (d, 2H), 1.54 – 1.39 (m, 9H).
[0089] LCMS m / z =483.2 [M-56+1] +.
[0090] Method 2:
[0091] To a 2L reaction flask, add 1.3 kg of dichloromethane, 120.03 g of intermediate 1C, and 108.76 g of INT-3 with stirring, followed by 149.55 g of N,N-diisopropylethylamine. After the addition is complete, cool the reaction solution to 15±5℃, and add 190.47 g of HATU in portions. After the addition is complete, maintain the temperature at 25±5℃ for approximately 16 hours, then stop the reaction.
[0092] The reaction solution was washed sequentially with sodium bicarbonate solution, citric acid solution, and sodium chloride solution. 1.0 kg of anhydrous sodium sulfate was added to the organic phase, and the mixture was dried for approximately 0.5 hours. The mixture was filtered, and the filter cake was washed with 1.905 kg of dichloromethane. The filtrates were combined.
[0093] The filtrate was concentrated under reduced pressure at 50±5℃ until no obvious fraction flowed out, yielding 221.30 g of intermediate 1D (overweight, calculated based on a 100% yield). This was used directly in the next reaction step.
[0094] Method 3:
[0095] To a 1L reaction flask, add 800g ethyl acetate, 100.0g intermediate 1C, and 53.26g INT-3 with stirring, followed by 80.11g N,N-diisopropylethylamine. After the addition is complete, under nitrogen protection, cool the reaction solution to 5±5℃, and add 197.66g propylphosphonic anhydride dropwise at a controlled temperature of 10±5℃. After the addition is complete, maintain the reaction temperature at 25±5℃ for approximately 2 hours. Monitor the reaction with HPLC; if the intermediate 1C content is ≤1.0%, stop the reaction.
[0096] The reaction solution was washed sequentially with sodium bicarbonate solution, citric acid solution, and sodium chloride solution. 200 g of anhydrous sodium sulfate was added to the organic phase, and the mixture was dried for approximately 0.5 hours. The mixture was filtered, and the filter cake was washed with 50 g of ethyl acetate. The filtrates were combined.
[0097] The filtrate was concentrated under reduced pressure at 50±5℃ until no obvious fraction flowed out, yielding 115.08 g of intermediate 1D (overweight, calculated based on a 100% yield). This was used directly in the next reaction step.
[0098] [Example] [4] []
[0099] (S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazacycloheptane-2-methylamine (Compound I)
[0100] (S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide (Compound I)
[0101] Method 1:
[0102] 9.305 kg of acetonitrile and 2.530 kg of p-toluenesulfonic acid monohydrate were added to a 50L double-walled glass reactor containing a concentrate of intermediate 1D (Method 1 of Example 3) with stirring. After the addition was complete, the mixture was kept at 25±5℃ for about 2 hours, and a sample was taken for HPLC monitoring. The reaction was stopped when the intermediate 1D content was ≤1.0% according to the target value.
[0103] The reaction solution was cooled to 10±5℃, and dilute ammonia solution (1.075 kg ammonia solution mixed with 36.000 kg purified water) was added dropwise, maintaining the temperature below 25℃ during the addition. After the addition was complete, the temperature was further cooled to 10±5℃ for crystallization over 2 hours. The mixture was filtered, and the filter cake was washed with 11.930 kg purified water. The filter cake and 14.890 kg ethanol were added to a 50 L double-walled glass reactor and stirred at 20±5℃ for 0.5 hours. The mixture was then filtered, and the filter cake was washed with 1.860 kg ethanol and collected. The filter cake was dried at 55±5℃ under a vacuum of ≤-0.07 MPa for approximately 13 hours, yielding 1.6627 kg of crude compound I, with a yield of 85.6%.
[0104] Purification: In a 100 L reactor, add 9.100 kg acetonitrile, 9.220 kg anhydrous ethanol, and 1.6627 kg crude compound I with stirring. Heat to an internal temperature of 75±5℃ and stir until dissolved. Filter while hot. Transfer the filtrate to a 100 L reactor (if product precipitates from the filtrate, heat to dissolve it completely). Stir and cool to 35±5℃, maintain this temperature until a distinct solid precipitates, and then maintain this temperature with stirring for about 0.5 hours. Then cool to 5±5℃ and maintain this temperature for 2 hours to allow crystals to crystallize. Filter, wash the filter cake with 1.300 kg ethanol, and collect the filter cake.
[0105] Drying: The filter cake was dried at 55±5℃ and a vacuum of ≤-0.07MPa for about 25 hours to give 1.4060 kg of compound I, with a yield of 84.6%. The overall yield was 55.0% (based on compound 2a), HPLC: 99.93%.
[0106] 1H NMR (400 MHz, DMSO) δ 8.69 (d, 1H), 7.64 (d, 1H), 7.61 – 7.51 (m, 2H), 7.46 (t, 2H), 7.39 (d, 1H), 5.06 (q, 1H), 4.01 (dd, 1H), 3.87 (ddd, 1H), 3.73 (ddd, 1H), 3.40 (s, 3H), 3.34 – 3.28 (m, 1H), 3.20 (dd, 1H), 3.06 (dd, 1H), 2.78 (ddd, 1H), 2.69 – 2.54 (m, 2H), 2.21 (s, 1H), 1.84 – 1.63 (m, 2H).
[0107] LCMS m / z =439.2 [M+1] +.
[0108] Method 2:
[0109] In a 100L double-walled glass reactor, 19.26 kg of acetonitrile, 3.712 kg of p-toluenesulfonic acid monohydrate, and 3.500 kg of intermediate 1D were added with stirring. After the addition was complete, the mixture was kept at 25±5℃ for about 2 hours, and then a sample was taken for HPLC monitoring. The reaction was stopped when the intermediate 1D content was ≤1.0% according to the target value.
[0110] The reaction solution was concentrated to approximately 20 L, cooled to 10 ± 5 °C, and dilute ammonia solution (4.0 kg ammonia solution mixed with 56.00 kg purified water) was added. After the addition was complete, the temperature was further lowered to 10 ± 5 °C to allow crystallization for 0.5 hours. The mixture was filtered, and the filter cake was washed with 5 kg purified water and collected. The filter cake was dried at 55 ± 5 °C under a vacuum of ≤ -0.07 MPa for approximately 72 hours, yielding 2.552 kg of crude compound I.
[0111] Purification: In a 100 L reactor, add 19.63 kg of isopropanol and 1.6627 kg of crude compound I with stirring. Heat to an internal temperature of 75±5℃ and stir for about 2 hours. Then cool to 25±5℃ and maintain the temperature for crystallization for about 16 hours. Filter, wash the filter cake with 1.300 kg of isopropanol, and collect the filter cake.
[0112] Drying: The filter cake was dried at 55±5℃ and vacuum degree ≤-0.07MPa for about 24 hours to obtain 2.344.2 kg of compound I, with a yield of 82.3%.
[0113] [Biological Testing] []
[0114] [1] [,in vitro] [DPP1] [Enzyme activity detection experiment] []
[0115] Recombinant human DPP1 enzyme (R&D Systems, Cat. No. 1071-CY) at a final concentration of 100 μg / mL was mixed with recombinant human cathepsin L (R&D System, Cat. No. 952CY) at a final concentration of 20 μg / mL and incubated at room temperature for 1 hour to activate the DPP1 enzyme. The activated DPP1 enzyme was diluted 100-fold, and 5 µL of different concentrations of the compound and 5 µL of diluted DPP1 enzyme were added to 384-well plates, incubated at room temperature for 30 minutes. Then, 10 µL of 20 µM substrate Gly-Arg-AMC (bachem, Cat. No. I-1215) was added, and incubation continued at room temperature for 60 minutes. Fluorescence intensity was measured using a microplate reader, with excitation at 380 nm and emission at 460 nm. The IC50 value was calculated using the DosResp function in Origin 2019 software. Table 1 DPP1 inhibitory activity Compound numbering IC 50 / nM Compound I 1.6
[0116] Conclusion: The compounds of this invention exhibit high inhibitory activity against the DPP1 receptor.
[0117] [2] [Rat Pharmacokinetics Test] []
[0118] 1.1 Experimental animals: Male SD rats, approximately 220 g in size, 6-8 weeks old, 6 rats per compound. Purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0119] 1.2 Experimental Design: On the day of the experiment, 6 SD rats were randomly divided into groups according to their body weight. They were fasted for 12-14 hours before drug administration but allowed free access to water. They were fed 4 hours after drug administration. Table 2 Dosage Information Group quantity Drug information male test substance Dosage (mg / kg) Dosage concentration (mg / mL) Dosage volume (mL / kg) Sample collection Dosage Way G1 3 INS1007 1 0.2 5 plasma vein G2 3 Compound I 1 0.2 5 plasma G3 3 INS1007 3 0.3 10 plasma Gavage G4 3 Compound I 3 0.3 10 plasma
[0120] Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline; Gavage administration solvent: 0.5% MC; Control compound INS1007, namely compound 2 in patent WO2015110826A1, was prepared according to the patented method.
[0121] Blood samples of 0.1 ml were collected via the orbital cavity before and after isoflurane anesthesia, placed in EDTAK2 centrifuge tubes, and centrifuged at 5000 rpm and 4 °C for 10 min to collect plasma. Blood collection times for the intravenous group were: 0, 5, 15, 30 min, 1, 2, 4, 6, 8, and 24 h; blood collection times for the gavage group were: 0, 5, 15, 30 min, 1, 2, 4, 6, 8, and 24 h. All samples were stored at -80 °C before analysis. Table 3. Pharmacokinetic parameters of the tested compounds in rat plasma Subject compound Administration method CL (mL / min / kg) Vdss (L / kg) AUC0-t (hr*ng / mL) F (%) INS1007 vein (1 mg / kg) 2.08 0.738 8396 - Compound 1 1.66 0.753 9503 - INS1007 Gavage (3 mg / kg) - - 22201 88.1 Compound 1 - - 31159 >100
[0122] Conclusion: The compounds of this invention have good bioavailability and pharmacokinetic characteristics.
[0123] [3.] [Rat]
[14] [Daily oral repeated-dose toxicity test] []
[0124] SD rats were randomly divided into three groups according to body weight: a solvent control group (0.5% MC), an INS1007 (30, 100, 300 mg / kg) group, and a compound I (30, 100, 300 mg / kg) group, with 16 rats in each treatment group and 10 rats in each solvent control group. The rats were half male and half female. The appropriate concentration of drug or solvent was administered orally by gavage daily for 14 consecutive days, followed by a 7-day recovery period. During the treatment period, general symptoms, body weight, and food intake were monitored in each group. At the end of the treatment period and the end of the recovery period, hematological, serum biochemical, and gross anatomical examinations were performed on each group.
[0125] Conclusion: At the same dosage, the compounds of this invention are less toxic than INS1007 and have higher safety.
[0126] none
[0127] none
Claims
1. A method for preparing a compound of formula (I), comprising: a first step: coupling compound 2a and compound 1A to obtain intermediate 1B; and a second step: adding intermediate 1B and an acid to an organic solvent, reacting at a controlled temperature of 20-55°C until fully reacted, then filtering to obtain intermediate 1C or its salt; optionally, adding the filter cake to an organic solvent, heating to 80±5°C, stirring for 1-5 hours, cooling to 20±5°C, stirring, filtering, and drying to obtain intermediate 1C or its salt, wherein... The acid is selected from one or more of sulfuric acid, phosphoric acid, formic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid, and p-toluenesulfonic acid monohydrate; the organic solvent is selected from one or more of methanol, ethanol, isopropanol, acetonitrile, isopropyl acetate, ethyl acetate, toluene, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran, methyl tributyl ether, and acetonitrile.
2. The preparation method according to claim 1, characterized in that the first step includes dissolving compound 2a and compound 1A in an organic solvent, then adding a base, and after the addition is complete, adding a catalyst under nitrogen protection, and heating to 80±5℃ for complete reaction; then cooling to 5~55℃, stirring to precipitate crystals, filtering, and drying to obtain intermediate 1B; optionally, after filtration, adding the filter cake to an alcohol solvent, stirring for 10min~2h, then filtering and drying to obtain intermediate 1B; wherein... The organic solvent is selected from one or more of acetonitrile, toluene, dichloromethane, ethyl acetate, acetone, methanol, ethanol, isopropanol, 2-methyltetrahydrofuran, tetrahydrofuran, and 1,4-dioxane; the base is selected from one or more of K3PO4, K2HPO4, K2CO3, KHCO3, Cs2CO3, Na2CO3, NaHCO3, KF, sodium acetate, potassium acetate, pyridine, triethylamine, or N,N-diisopropylethylamine, or aqueous solutions thereof; the catalyst is selected from NiCl2, NiCl2·didimethylamine, etc. One or more of the following: Ni(COD)2, Pd(OAc)2, PdCl2, Pd(PPh3)2Cl2, Pd(dppf)Cl2, Pd(PPh3)4, Pd2(dba)3, Pd(PhCN)2Cl2, PEPPSI-iPr, PdCl2[P(Cy)3]2, and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex.
3. The preparation method according to claim 1 or 2, characterized in that it further comprises a third step: reacting intermediate 1C or its salt with compound INT-3 or its salt by a amide reaction to obtain intermediate 1D; or / and a fourth step: deprotecting intermediate 1D under acidic conditions to obtain compound (I) or its salt; 4. The preparation method according to claim 3, characterized in that the third step includes adding intermediate 1C or its salt, and compound INT-3 or its salt to an organic solvent, then adding an organic amine, and after the addition is complete, adding an acid-amine condensing agent dropwise under nitrogen protection at a controlled temperature of 5-20°C, and after the addition is complete, maintaining the temperature at 25±5°C for complete reaction; then, washing the reaction solution with sodium chloride solution, separating the liquid, adding activated carbon or pharmaceutical charcoal to the organic phase, stirring, filtering, adding anhydrous sodium sulfate to the organic phase for drying, filtering, concentrating, to obtain intermediate 1D or its salt; wherein the organic solvent is selected from one or more of tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, dichloromethane, acetone, methyl isobutyl ketone, isopropyl acetate, and ethyl acetate; The organic amine is selected from one or more of triethylamine, 2,6-dimethylpyridine, pyridine, DBU, and N,N-diisopropylethylamine; the acid-amine condensing agent is selected from one or more of HATU, COMU, EDCI, BOP, and propylphosphoric anhydride.
5. The preparation method according to claim 4, characterized in that, in the third step, the reaction solution is washed sequentially with an alkaline aqueous solution and an acidic aqueous solution before being washed with sodium chloride solution; the alkaline aqueous solution is selected from one or more of potassium phosphate solution, potassium carbonate solution, potassium bicarbonate solution, sodium carbonate solution and sodium bicarbonate solution; the acidic aqueous solution is selected from one or more of hydrochloric acid solution, sulfuric acid solution, phosphoric acid solution and citric acid solution.
6. The preparation method according to claim 3, characterized in that the fourth step includes adding intermediate 1D and an acidic reagent to an organic solvent, keeping the mixture at 25±5℃ for full reaction, then adding alkali dropwise to the reaction solution while controlling the temperature below 25℃, and then cooling the mixture to 10±5℃ to crystallize, filtering, and drying to obtain compound (I); optionally, after filtration, the filter cake is washed with purified water, and then the filter cake is added to an alcoholic reagent, stirred at 20±5℃, filtered, and dried to obtain compound (I) or its salt.
7. The preparation method according to claim 6, characterized in that the acidic reagent in the fourth step is selected from one or more of hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid and p-toluenesulfonic acid monohydrate; the organic solvent is selected from one or more of acetonitrile, methanol, ethanol, isopropanol, isopropyl acetate, ethyl acetate, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran and methyl tributyl ether; and the base is selected from one or more of dilute ammonia, LiOH, NaOH, KOH, K3PO4, K2CO3, KHCO3, Cs2CO3, Na2CO3, NaHCO3, or aqueous solutions thereof.
8. The preparation method according to claim 6 or 7, characterized in that it further comprises a purification step: adding the obtained compound (I) to anhydrous ethanol-water, acetonitrile-water, acetonitrile-anhydrous ethanol, acetonitrile-methanol, acetonitrile-isopropanol, acetonitrile-tert-butanol, or acetonitrile-n-butanol solution, heating to 75±5°C, stirring until dissolved, optionally performing hot filtration, cooling the filtrate while stirring to precipitate crystals, filtering, drying, to obtain purified compound (I).
9. The preparation method according to claim 8, characterized in that the crystallization by cooling and stirring is carried out in two steps: first, cooling to 35±5℃ and holding for crystallization for 20 min to 1.5 hours, and then cooling to 5±5℃ and holding for crystallization for 1 to 3 hours.
Citation Information
Patent Citations
(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
CN105980367A
